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Ischemia and reperfusion may damage myocytes and endothelium in 
jeopardized hearts. This study tested whether (1) endothelial dysfunction 
(reduced nitric oxide release) exists despite good contractile performance 
and (2) supplementation of blood cardioplegic solution with nitric oxide 
precursor L-arginine augments nitric oxide and restores endothelial func- 
tion. Among 30 Yorkshire-Duroc pigs, 6 received standard glutamate/ 
aspartate blood cardioplegic solution without global ischemia. Twenty-four 
underwent 20 minutes of 37 ° C global ischemia. Six received normal blood 
reperfusion. In 18, the aortic clamp remained in place 30 more minutes and 
all received 3 infusions of blood cardioplegic solution. In 6, the blood 
cardioplegic solution was unaltered; in 6, the blood cardioplegic solution 
contained L-arginine (a nitric oxide precursor) at 2 mmol/L; in 6, the blood 
cardioplegic solution contained the nitric oxide synthase inhibitor L-nitro 
arginine methyl ester (L-NAME) at 1 mmol/L. Complete contractile and 
endothelial recovery occurred without ischemia. In jeopardized hearts, 
complete systolic recovery followed infusion of blood cardioplegic solution 
and of blood cardioplegic solution plus L-arginine. Conversely, contractility 
recovered approximately 40% after infusion of normal blood and blood 
cardioplegic solution plus L-NAME. Postischemic nitric oxide production 
fell 50% in the groups that received blood cardioplegic solution and blood 
cardioplegic solution plus L-NAME but was increased in the group that 
received blood cardioplegic solution L-arginine. In vivo endothelium- 
dependent vasodilator esponses to acetylcholine recovered 75% - 5% of 
baseline in the blood eardioplegic solution plus L-arginine group, but less 
than 20% of baseline in other jeopardized hearts. Endothelium-indepen- 
dent smooth muscle responses to sodium nitroprusside were relatively 
unaltered. Myeloperoxidase activity (neutrophil accumulation) was similar 
in the blood cardioplegic solution (without ischemia) and blood cardiople- 
gic solution plus L-arginine groups (0.01 -- 0.002 vs 0.013 ----- 0.003 pg/gm 
tissue). Myeloperoxidase activity was raised substantially to 0.033 _ 0.002 
ftg/gm after exposure to normal blood and to 0.025 __+ 0.003 pg/gm after 
infusion of blood cardioplegic solution and was highest at 0.053 -.+ 0.01 
pg/gm with exposure to blood cardioplegic solution plus L-NAME in 
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jeopardized hearts. The discrepancy between contractile recovery and 
endothelial dysfunction in jeopardized muscle can be reversed by adding 
L-arginine to blood cardioplegic solution. (J Thorac Cardiovasc Surg 1997; 
113:379-89) 
E arly death may follow technically successful elec- tive or emergency operations in patients with 
good ventricular performance. The causes of cardiac 
depression are complex and sometimes may involve 
injury of vascular endothelium. 1 This may occur 
within minutes after reperfusion and may result in 
neutrophil-mediated r perfusion i jury. Endothelial 
damage may also cause myocyte dysfunction be- 
cause of imbalance between vasodilator (such as 
nitric oxide [NO]) and vasoconstrictor substances 
and precede myocyte injury in jeopardized hearts. 
NO is produced from the amino acid L-arginine 
that combines with molecular oxygen and produces 
citrulline via constitutive NO synthase. If ischemia- 
reperfusion injury causes endothelial dysfunction, 2 
subsequent release of NO decreases, 3 vasorelax- 
ation is altered, 4 platelet aggregation is increased, 5 
and leukocyte adherence to vascular endothelium is 
enhanced with a concomitant increase in cytotoxic 
oxygen radical production. 6 Impaired NO genera- 
tion decreases the endogenous neutralization of 
superoxide radicals 7 and may predispose jeopar- 
dized myocardium to exacerbated reperfusion i jury 
and poor postischemic ontractile performance. 
These adverse endothelial effects in regional isch- 
emia were reduced by adding L-arginine to cold 
blood cardioplegic solution, but contractility re- 
mained depressed markedly. 8 
In this study, a model of damaged myocardium 
was produced by 20 minutes of unprotected normo- 
thermic ischemia (aortic clamping), followed by 30 
minutes of protected ischemia with blood cardiople- 
gic solution that completely restores contractile 
recovery. 9 These solutions were either a standard 
amino acid-enhanced formulation or one supple- 
mented with either L-arginine, the precursor to NO, 
or L-nitro arginine methyl ester (L-NAME), a com- 
petitive inhibitor of NO synthase. Results unmask a 
limitation of this blood cardioplegic solution that 
allows full recovery of postischemic contractile func- 
tion, but produces endothelial dysfunction expressed 
as decreased receptor-dependent vasodilation and 
increased myocardial neutrophil accumulation in 
myocardium. These changes are reversed by adding 
L-arginine to the cardioplegic solution. 
Material and methods 
All animals received humane care in compliance with 
the "Principles of Laboratory Animal Care" formulated 
by the Institute of Laboratory Animal Resources and the 
"Guide for the Care and Use of Laboratory Animals" 
prepared by the Institute of Laboratory Animal Resources 
and published by the National Institutes of Health (NIH 
Publication o. 86-23, revised 1985). 
Thirty Yorkshire-Duroc miniature pigs (24 to 26 kg 
weight, age 5 to 6 months) were premedicated (ketamine, 
5 mg/kg intramuscularly) and anesthetized with pentobar- 
bital, 30 mg/kg, intravenously and subsequent bolus injec- 
tions of sodium pentobarbital. Support with a volume- 
controlled ventilator (Servo 900D, Siemens-Elema, 
Sweden) was started after tracheostomy and endotracheal 
intubation. The femoral artery and vein were cannulated 
and arterial blood gases measured to keep oxygen tension, 
carbon dioxide tension, and pH values within the normal 
range. Solid-state pressure transducer-tipped catheters 
(Millar Instruments, Inc., Houston, Tex.) were inserted 
into the left ventricle and carotid artery to measure left 
ventricular (LV) and aortic pressures, respectively, and a 
saline solution-filled catheter connected to a jugular vein 
pressure transducer recorded central venous pressure. 
The pericardium was incised after median sternotomy 
and intravenous heparin (300 units/kg) was given. A saline 
solution-filled catheter inthe left atrium was connected to
a pressure transducer. A balloon-tipped catheter in the 
pulmonary artery measured cardiac output (thermodilu- 
tion technique) and pulmonary artery pressure. 
A 16F femoral arterial catheter and 30F right atrial 
catheter were placed. A dual-lumen aortic cannula mea- 
sured delivery of blood cardioplegic solution and aortic 
pressure. The blood cardioplegic solution was hyperkale- 
mic (20 mg KC1/L), alkalotic (tromethamine), hypocalce- 
mic (0.2 mEq/L Ca2+), and enriched with glutamate/ 
aspartate as reported previously) ° The coronary sinus was 
cannulated transatrially for blood sampling, and the LV 
was vented. An octapolar impedance catheter (Webster, 
Anaheim, Calif.) was inserted into the LV apex. The 
correct position was determined by the phasic wave 
pattern in the individual electrode pairs. The conductivity 
of blood was determined periodically by a standardized 
conductance cuvette. The conductance signal was pro- 
cessed by a Leycom Sigma 5 signal conditioner and 
processor (Oegstgeest, The Netherlands). Parallel con- 
ductance of structures contiguous with the LV was peri- 
odically corrected by the hypertonic saline technique, n 
Extracorporeal circulation was achieved with a mem- 
brane oxygenator (Sarns 1630 membrane oxygenator, 
Sarns, Ann Arbor, Mich.) and an extracorporeal pump 
(Sarns) with the circuit primed with 1000 ml Plasma-Lyte 
solution (Baxter Healthcare Corp.), 700 ml stored porcine 
packed red blood cells, and calcium chloride for normo- 
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Fig. 1. Schematic diagram of the experimental protocol. The normal blood group was placed on bypass 
and subjected to 20 minutes of normothermic schemia, followed by normal blood reperfusion. Blood 
cardioplegia (BCP) groups were subjected to global ischemia and blood cardioplegic solution with or 
without L-arginine (L-arg) or L-NAME. A control BCP group was not jeopardized by normothermic 
ischemia but received amino acid-enhanced blood cardioplegic solution. 
calcemia (1.0 to 1.2 mmol/L). Potassium, calcium, and pH 
were kept at normal evels. 
Experimental protocol. In 30 pigs, cardiopulmonary 
bypass (CPB) was started at an oxygen tension of 300 mm 
Hg and an aortic pressure of 50 to 60 mm Hg by adjusting 
pump flow to approximately 80 ml/kg per minute. The 
experimental protocol is shown in Fig. 1. 
Control blood cardioplegic group. Six normal hearts 
without ischemia received the blood cardioplegia protocol 
(unjeopardized hearts; control BCP group). 
Ischemic groups 
NORMAL BLOOD REPERFUSION. Six pigs underwent 20 
minutes of normothermic aortic clamping followed by 
reperfusion with normal blood. CPB was continued for 30 
more minutes and final metabolic and functional mea- 
surements were made 30 minutes later. 
BLOOD CARDIOPLEGIC SOLUTION REPERFUSION. In 18 
pigs, the aorta was clamped for 20 minutes of normother- 
mic ischemia followed by 30 minutes of arrest with the use 
of blood cardioplegia; all hearts received a 4:1 blood 
cardioplegic solution delivered at 200 ml/min. The cardio- 
plegia protocol included warm induction (2 minutes) 
followed by cold maintenance (repeated in 15 minutes) 
and infusion of warm reperfusate before unclamping. 
BLOOD CARDIOPLEGIC SOLUTION WITHOUT NO-RELATED 
ADDITIVES. In six pigs, the blood cardioplegic solution did 
not contain NO-related agents (BCP group). 
BLOOD CARDIOPLEGIC SOLUTION PLUS L-ARGININE. In six 
pigs, the final blood cardioplegic solution contained L- 
arginine at 2 mmol/L (BCP plus L-arginine group). 
BLOOD CARDIOPLEGIC SOLUTION PLUS L-NAME. In six 
pigs, the solution contained L-NAME (1 mmol/L blood 
cardioplegic solution) to inhibit the endogenous genera- 
tion of NO by NO synthase (BCP plus L-NAME group). 
Measurements. Global LV function before and after 
CPB was assessed by (1) Starling function curves and (2) 
pressure-volume analysis with end-systolic elastance. In 
Starling curves, preload was raised by continuously infus- 
ing blood intravenously at 4 ml/kg per minute while 
cardiac output and mean arterial and left atrial pressure 
were recorded. Cardiac output was determined by dupli- 
cate central venous injections of 3 ml of 4°C saline 
solution, and left ventricular stroke work index (LVSWI) 
was calculated. LV systolic function was assessed from the 
linear end-systolic pressure-volume r lationship during 
transient caval occlusions to obtain a series of evenly 
declining pressure-volume loops. With use of a video 
graphics program (SPECTRUM, Triton Technology, Inc., 
San Diego, Calif.), the end-systolic point for each loop was 
identified using the algorithm of Kono and associates. 12
Linear regression was done on the corrected (parallel 
conductance) end-systolic pressure-volume points, and 
the slope and volume axis intercept were used to assess 
elastance and position of the pressure-volume r lation. 
Chamber stiffness was calculated from the exponential 
end-diastolic pressure-volume r lationship obtained ur- 
ing the same transient bicaval occlusion period and was 
described by the unitless coefficient or modulus of stiff- 
ness. Postbypass LV performance was expressed as per- 
cent of recovery from prebypass values. 
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Fig. 2. LV performance assessed by Starling curves. LAP, Left atrial pressure; BCP, blood cardioplegic 
solution; blood, reperfusion with unmodified blood; L-arg, i=arginine. 
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Fig. 3. Recovery of LV end-systolic elastance, expressed as a percent of preischemic control values. EES, 
End-systolic elastance; other abbreviations as in Fig. 2. 
In vivo coronary vascular esponses. Coronary vascular 
responses to the stimulators of NO synthase acetylcholine 
(an endothelial receptor-dependent agonist) and nitro- 
prusside (an endothelium-independent, smooth muscle 
agonist) were made before (preischemia, acetylcholine, 
nitroprusside only) and after the measurement protocol 
was completed (postischemia, cetylcholine, nitroprusside 
and A23187 infusions) by a constant flow technique. The 
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Fig. 4. LV chamber stiffness, expressed as a percent increase from baseline control values in the/3 coefficient. 
*p < 0.05 versus normal blood group and BCP plus L-NAME group. Abbreviations as in Fig. 2. 
aorta was clamped and the root perfused with blood at 50 
mm Hg (approximately 100 ml/min). Heart rate was 
atrially paced at 170 beats/rain. After 5 minutes' stabiliza- 
tion, 5 ml acetylcholine (10 4 ml/L) was injected as a 
bolus. After washout and stabilization, the endothelium- 
independent agonist sodium nitroprusside followed by the 
endotheiium-dependent receptor-independent calcium 
ionophore (6.7 × 10 5 mol/L) were infused. Because of 
toxic effects of A23187, baseline dilator responses were 
only made in nonischemic hearts. Coronary vascular e- 
sponses were calculated as percent decrease in coronary 
pressure compared with baseline pressure responses. 
Myocardial release of NO. Myocardial release of NO 
was analyzed from the aorta and coronary venous effluent. 
Coronary blood flow was the rate of pump delivery 
volume and the arteriovenous NO difference was used to 
calculate NO production. Samples were centrifuged im- 
mediately at 4°C and 3000 rpm for 5 minutes and the 
plasma was stored in liquid nitrogen. NO concentration 
was determined by reconverting its oxidation end-prod- 
ucts (nitrite, NOa- ) and nitrate (NOB) and measured by 
chemoluminescence (Chemiluminescence NO n Analyzer, 
model 2108, Dosibi Environmental Corp., Glendale, 
Calif.)J 3 Myocardial release of NO was expressed in 
millimolars per minute per 100 gm of heart muscle. 
Myeloperoxidase activity. Final transmural samples of 
LV myocardium (approximately 0.5 gin) from the anterior 
free wall were immediately frozen in liquid nitrogen until 
analyzed. Samples were analyzed for neutrophil-specific 
myeloperoxidase activity as previously described, s"14 Myelo- 
peroxidase activity is expressed in units per gram of tissue. 14 
At the end of the experiment, he pigs were killed by 
bolus injection of 15 ml cold hyperkalemic blood (KC1, 30 
mEq/L) and the hearts were harvested for determination 
of weight and myeloperoxidase activity. 
Statistical analyses. All data are given as mean plus or 
minus standard error of the mean. Individual differences 
between baseline and reperfusion values were determined 
with the Student's t test for paired data. Comparison of 
group functional and biochemical data was done by 
analysis of variance. Analyses were made with use of the 
StatView No. 2 software package 2.0 (Abacus Concepts, 
Berkeley, Calif.) on a Macintosh IIci computer (Apple 
Inc., Cupertino, Calif.). Significance was accepted at ap < 
0.05 level of probability. 
Results 
LV performance. Twenty minutes of normother-  
mic ischemia and blood reperfusion recovered only 
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Fig. 5. Transmyocardial NO production (NO 2 plus NO3) 
after normothermic is hemia or during delivery of blood 
cardioplegic solution in absence of ischemia (BCP group) 
measured by chemoluminescence. Units are millimolars 
per minute per 100 gm heart tissue. Abbreviations a in 
Fig. 2. 
37% _+ 7% of LVSWI at a left atrial pressure of 12 
mm Hg (Fig. 2). In the control BCP group, LVSWI 
recovered to 96% ,+ 5% of baseline. Recovery was 
comparable in the unprotected ischemia plus BCP 
(90% -+ 5% of baseline) and BCP plus L-arginine 
groups (97% + 7%). This was greater than the recov- 
ery in the unmodified blood group. Conversely, the 
inclusion of L-NAME reversed this functional recovery 
to 56% .+ 4% of baseline, comparable to that with 
unmodified blood reperfusion. 
Without ischemia, blood cardioplegic solution 
caused complete recovery of end-systolic elastance 
(Ees) relative to baseline (100% _+ 2%). LV elas- 
tance (Ees) was 70% ,+ 6% of baseline in the 
normal blood reperfused group (Fig. 3). After isch- 
emia plus standard blood cardioplegic solution, re- 
covery of elastance (Ees) was 100% _+ 4% and 
similar to that in the BCP plus L-arginine group 
(98% __ 3%), which exceeded that in the unmodified 
blood group. Conversely, L-NAME reduced recov- 
ery to 75% _+ 8%, which was comparable to that in 
the normal blood group. 
After normal blood reperfusion, the modulus of 
stiffness (unitless /9 coefficient) rose 50% .+ 5% 
higher than baseline compared with no change in 
the control BCP group. In contrast, there was 
significantly less increase in stiffness in the BCP 
(10% + 4% higher than baseline) and BCP plus 
L-arginine (7% _+ 4% higher than baseline) groups 
(Fig. 4). The addition of L-NAME to blood car- 
dioplegic solution raised postischemic stiffness to 
31% _+ 7% higher than baseline, similar to that after 
unmodified blood reperfusion. 
NO production. Immediately after ischemia, the 
BCP plus L-arginine group had the greatest NO 
production (1.25 _ 0.1 mmol/min per 100 gin), 
which was significantly greater than that in the 
unmodified blood reperfusion (0.6 ___ 0.06) and BCP 
(0.65 +_ 0.05) groups (Fig. 5). NO production fell 
progressively to normal when final vasodiiator re- 
sponses were measured (Fig. 6), suggesting that the 
L-arginine effect on NO was absent. NO production 
was normal with BCP plus L-arginine and fell 50% 
lower than normal in the groups receiving normal 
blood and blood cardioplegic solution alone. NO 
production was not measured in the group treated 
with L-NAME because the acidic conditions of 
chemoluminescence assay falsely elevate NO con- 
centration from L-NAME. 
Coronary vasodilation with aeetyleholine. Coro- 
nary endothelial receptor-dependent vasodilation 
recovered 75% _+ 10% of the baseline level in the 
BCP plus L-arginine group and 75% _+ 5% of the 
baseline level in the control (no antecedent isch- 
emia) BCP group (Fig. 7,A). In contrast, vasodilator 
responses with acetylchoiine were impaired to 25% 
+ 10% of baseline in the normal blood reperfusion 
group and to 20% _+ 5% of baseline in the BCP 
group. No vasodilation responses (0%) were ob- 
served in the BCP plus L-NAME group. 
Vasodilation to A23187. Under control condi- 
tions, the vasodilator response to A23187 averaged a 
20% decrease in pressure during constant flow. In 
the unmodified (normal) blood reperfusion group, 
the hypotensive r sponse to A23187 fell to approx- 
imately 50% of baseline values (Fig. 7, B). In 
contrast, postischemic vasodilator esponses to 
A23187 were 75% of baseline in the BCP group and 
significantly greater in the BCP plus L-arginine 
group in which they slightly exceeded baseline vaso- 
dilator esponses. With L-NAME treatment, vasodi- 
lator responses were reduced to approximately 60% 
of baseline and were significantly ess than those in 
the BCP plus L-arginine group. 
Vasodilation with nitroprusside. Endothelium- 
independent vasodilation with nitroprusside r cov- 
ered to 70% or more of baseline responses in all 
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Fig. 6. Basal transmyocardial NO release (NO2 plus NO3) after 30 minutes of reperfusion. Abbreviations 
as in Fig. 2. 
groups, as shown in Fig. 7, C. The highest recovery 
was observed in the BCP plus L-NAME, BCP plus 
c-arginine, and control BCP groups, despite absence 
of acetylcholine r sponses. Pressure was reduced by 
approximately 50% with L-NAME, which indicated 
a greater vascular esistance that may have been 
more fully relaxed by nitroprusside. Therefore the 
vasodilatory esponses may have been greater in this 
group. 
Myeloperexidase activity. Myeloperoxidase ac- 
tivity averaged 0.033 + 0.002 units/gm after unpro- 
tected ischemia and unmodified blood reperfusion 
and 0.025 +_ 0.003 units/gin in the BCP group and 
rose to 0.053 + 0.01 units/gm after BCP plus 
L-NAME. In contrast, myeloperoxidase activity was 
significantly lower in the BCP plus L-arginine 
(0.013 _+ 0.003 units/gm) and the control BCP 
groups (0.01 _+ 0.002 units/gin), as shown in Fig. 8. 
Discussion 
In this study, the benefits of blood cardioplegic 
solution supplemented with the precursor to NO, 
L-arginin@ 5 were assessed in myocardium jeopar- 
dized by 20 minutes of normothermic global isch- 
emia (unprotected ischemia) before protection with 
blood cardioplegic solution. These studies showed 
that a blood cardioplegic solution that allows corn- 
plete myocardial systolic and diastolic functional 
recovery was associated with endothelial dysfunc- 
tion primarily expressed as blunted receptor-medi- 
ated vasodilator esponses to stimulators of NO 
synthase. Endothelial dysfunction was improved and 
neutrophil accumulation reduced by supplementa- 
tion of the cardiop!egic solution with L-arginine. 
L-arginine enhanced the transmyocardial production 
or release of NO. The competitive inhibitor of 
NO-synthase, L-NAME, reduced NO production 
and exacerbated postischemic contractile dysfunc- 
tion, endothelial dysfunction, and myocardial neu- 
trophil accumulation. These observations confirm 
the participation of basal NO in endogenous protec- 
tion of the myocardium in surgical ischemia, 16 car- 
dioplegia, and reperfusion as observed by others 
with use of models of combined contractile and 
endothelial dysfunctionJ 7 
Tsao and Lefer 18 showed that endothelial cell 
dysfunction occurs moments after reperfusion fol- 
lowing regional ischemia and progresses with time. 
This dynamic endothelial cell dysfunction produces 
a reduction in NO generation, which leads to in- 
creased vasoconstriction and enhanced neutrophil 
adhesion and accumulation. Consistent with this 
concept of rapid endothelial cell damage during 
regional ischemia-reperfusion, Nakanishi and col- 
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Fig. 7. Hypotensive responses to agonist stimulators f NO or direct smooth muscle dilators during 
constant aortic root flow. A, Hypotensive responses to endothelium-dependent, muscarinic receptor- 
dependent acetylcholine. B, Hypotensive response to the endothelium-dependent receptor-independent 
calcium ionophore A23187. C, Responses to the direct smooth muscle dilator sodium nitroprusside (SNP). 
Data represent percent of control (preischemic) hypotensive response. The dashed lines represent 
responses obtained in a series of normal hearts not subjected to ischemia, blood cardioplegic solution, r 
reperfusion. Cor., Coronary; other abbreviations as in Fig. 2. 
leagues 14 demonstrated endothelial injury after 
blood cardioplegia in which morphologically and 
functionally apparent endothelial injury occurred 
during the reperfusion phase, rather than during 30 
to 45 minutes of antecedent ischemia or blood 
cardioplegic arrest. Studies show endothelial injury 
(dysfunction) in neonatal hearts administered crys- 
talloid cardioplegia, 2' 19 and this was associated with 
myocyte injury as well. In contrast, the ischemia 
imposed in the present s udy did not produce myo- 
cyte contractile dysfunction, but did produce ndo- 
thelial dysfunction. However, vasodilator responses 
to the nonreceptor endothelial agonist A23187 were 
largely intact in the BCP group, suggesting that the 
dysfunction was at the muscarinic receptor or its 
signal transduction mechanism, rather than involv- 
ing NO synthase or the vascular smooth muscle 
(sodium nitroprusside response). Therefore the cur- 
rent study suggests that (1) the endothelium may be 
more vulnerable to injury than the myocyte, or that 
endothelial injury precedes myocyte injury, and (2) 
injury to the endothelium (that is, stunning) does 
not always lead to contractile injury. 
The lack of consistency between the presence of 
endothelial dysfunction and contractile dysfunction 
raises the question whether injury to the endothe- 
lium leads to loss of contractility. The initial inter- 
action between endothelium and neutrophil may 
initiate neutrophil-mediated damage. However, 
with less severe injury, which may damage the 
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Fig. 8. LV anterior free wall myocardial myeloperoxidase (MPO) activity taken at the end of the 
reperfusion period. Abbreviations as in Fig. 2. 
endothelium but not precipitate necrosis, the neu- 
trophil component may not be important o stun- 
ning. Evidence suggests that neutrophils may not be 
involved in the pathogenesis of myocardial stun- 
ning. 2° How endothelial dysfunction relates to con- 
tractile dysfunction in stunning requires further 
clarification. 
The benefit of c-arginine supplementation in car- 
dioplegic solution is predicated on incorporation of 
the NO precursor into cells and subsequent aug- 
mentation of NO production. 21It has been shown 
that supplemental L-arginine is taken up by vascular 
endothelial cells, is' 22 particularly in cells starved of 
the amino acid. Enhanced uptake is accompanied by 
enhanced release of NO. Our data support his by 
showing that L-arginine in blood cardioplegic solu- 
tion augmented total nitrate/nitrite levels, largely 
representing NO. In addition, vasodilator agonists 
like acetylcholine stimulate both the uptake of L- 
arginine and the release of NO, 23 whereas depletion 
of L-arginine reduces the release of NO.  24 Ma and 
associates 25 and others showed that inhibition of 
basal release of NO with L-NAME increased neu- 
trophil adherence to endothelium. This increased 
adherence was reversed completely by the addition 
of L-arginine, which suggests that endothelium-de- 
rived NO is an important intrinsic modulator of 
leukocyte adherence. 26In addition, Sato, Zhao, and 
Vinten-Johansen z7 reported that L-arginine, but not 
D-arginine, inhibited neutrophil adherence to coro- 
nary endothelium, which was reversed by NO-syn- 
thase inhibitors. Accordingly, supplemental L-argi- 
nine has been shown to reduce necrosis and 
endothelial injury in models of coronary occlusion- 
reperfusion28, 29 and global ischemia followed by 
cardioplegia.8, 14 This protection is mediated by 
enhanced NO and targets primarily neutrophil-me- 
diated damage. L-Arginine has no direct inhibitory 
effect on neutrophils. 27In this study, the severity of 
injury after ischemia nd blood cardioplegia did not 
cause contractile dysfunction (myocyte), but pro- 
duced endothelial cell dysfunction. L-Arginine in 
blood cardioplegic solution prevented both manifes- 
tations. The improved coronary vasodilator re- 
sponse was most likely not related to persistently 
high levels of L-arginine inas much as NO levels 
returned to baseline when postischemic vasodilator 
responses were tested. A more likely explanation is
that L-arginine reduced neutrophil accumulation 
(consistent with the myeloperoxidase data) and sub- 
sequent endothelial damage. L-Arginine may pro- 
tect the endothelium through antineutrophil and 
direct quenching of superoxide by NO. 3° 
An alternative mechanism of protection relates to 
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the vasodilator action of NO. Perfusion defects may 
be related to increased vascular resistance as a result 
of impaired production of NO, producing a greater 
balance of vasoconstrictor agents such as endothe- 
lin-1 or enhanced neutralization of NO by superox- 
ide radical anions. In the absence of NO, endothe- 
lin-1 production would increase, resulting in 
increased vascular resistance and decreased perfu- 
sion. These changes could explain the potential for 
perioperative vasospasm or graft closure in certain 
patients. 
We conclude that (1) endothelial dysfunction can 
occur in the absence of contractile dysfunction, (2) 
L-arginine supplementation reverses this endothelial 
injury possibly by enhancing NO production and 
inhibiting neutrophil-mediated amage, and (3) 
basal NO participates in endogenous protection 
during surgically related ischemia and reperfusion. 
Protection of the endothelium by c-arginine may 
reduce the contribution of endothelial injury to the 
progression of surgical reperfusion injury. Inclusion 
of L-arginine in cardioplegic solutions may be a 
novel, low-cost adjuvant. 
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Discussion 
Mr. Magdi H. Yacoub (London, United Kingdom). I
have two questions. The first is, how did the authors 
measure pressure volumes? Was this an ex vivo model 
that just looked at the pressure versus the volume as in the 
Weber and Jenneke model, or did they really measure the 
pressure-volume relationship in an ejecting heart? 
The second question is, one of the products of interac- 
tion between NO and oxygen radicals is the formation of 
peroxynitrite: do the authors think that had anything to do 
with the difference between myocardial and endothelial 
recovery, and have they measured a product like nitrothy- 
roxine, for example? 
Dr. Mizuno. We used a pressure-volume loop in in vivo 
models and measured the decline of the linear regression 
curve. Compared with control values, the linear regression 
curve was called 100%, and after completion of the 
protocol we measured the percentage recovery of this 
level. 
Mr. Yacoub. You used a conductance catheter? 
Dr. Mizuno.. Yes, a conductance catheter. 
Dr. Jakob Vinten-Johansen. The question of nitrothy- 
roxine and peroxynitrite is an excellent one, Mr. Yacoub, 
that stems from the controversial theory of NO potentially 
playing a dual role, that is, as a potent antineutrophil 
agent and a source of deleterious metabolites such as 
peroxynitrite. In the surgical setting used in the experi- 
ment in which endogenous NO levels are modulated, 
sufficient levels of NO may not have been achieved to 
produce significant amounts of peroxynitrite and other 
deleterious metabolites such as hydroxyl radicals. There- 
fore the beneficial effects of NO, including neutrophil 
inhibition, may have been predominantly expressed. Cer- 
tainly, if NO achieves higher levels through overexpres- 
sion, as it does in circulatory shock, peroxynitrite and its 
metabolites may exert a significant pathologic effect. We 
do not measure nitrothyroxine. 
Dr. Frank W. Sellke (Boston, Mass.). Where was the 
NO that the authors measured, and how did they measure 
it? 
Dr. Mizuno. We compared NO2 and NO 3 with NO and 
used the chemoluminescence m thod° 
Dr. Sellke. Did you look at baseline coronary perfusion 
to see whether the endothelial dysfunction correlated with 
a change in basal perfusion? 
Dr. Mizuno. We made baseline measurements of coro- 
nary perfusion. After the reperfusion we measured the 
NO and in the injured group and the BCP group found 
the flow to have declined to less than the normal level, 
whereas L-arginine was maintained at the normal evel, 
Dr. Sellke. This is coronary perfusion, coronary blood 
flow, that the authors looked at? 
Dr. Mizuno. We measured coronary flow by a con- 
trolled infusion of blood with the aorta clamped. We also 
measured NO production as we took a sample from the 
arterial side and the coronary sinus side. The production 
was the flow times the arteriovenous difference. 
Dr. Sellke. My final comment is, how do the authors 
think L-arginine works? Do they think it is just increasing 
substrate availability, or is it reducing the inhibitory effects 
of glutamine and other inhibitors of NO synthase, or is it 
some other mechanism? Do they think it has a direct 
effect on white cell activation? 
Dr. Mizuno. We think L-arginine increased the NO 
synthase pathway and raised NO production by this 
predominant pathway. This decreased white blood cell 
aggregation i the endothelium, as shown by the myelo- 
peroxidase study, in which myeloperoxidase activity was 
very high with L-NAME. This NO production may also 
limit platelet aggregation and have a quenching effect on 
superoxide anion. Consequently, the role of L-arginine 
may be a broad spectrum of activities. We do not believe 
L-arginine has a direct effect on neutrophils, and acts via 
the NO synthase pathway. 
Dr. Robert A. Guyton (Atlanta, Ca.). I want to return to 
the question of coronary vasodilation and how the authors 
measured perfusion and coronary flow. I am curious that 
they used pressure rather than flow or coronary resistance. 
Did the authors hold perfusion constant and look at 
pressure? Also with regard to Dr. Sellke's question, what 
was the baseline flow in the BCP group? Was it less than 
the baseline flow in the BCP group than in the BCP plus 
L-arginine group? 
Dr. Mizuno. We maintained a coronary pressure of 50 
mm Hg and generally set a constant flow of 200 mm Hg in 
control studies and in studies with blood cardioplegic 
solution with and without L-arginine. Consequently, any 
reduction in coronary pressure was a fall in perfusion after 
infusion of acetylcholine or nitroprusside. The baseline 
point was less after perfusion with L-NAME, so we may 
have overestimated the response in some cases. The drop 
in pressure was used to determine response. 
Dr. Guyton. Do you know what the baseline differences 
were between the two groups? 
Dr. Mizuno. During the preliminary experiments we did 
use reperfusion, but baseline pressure was the same 
before reperfusion and addition of the acetylcholine, 
calcium ionophore, or sodium nitroprusside. Conse- 
quently, there was no difference before drug injection. 
